APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174002350326 December 2025193 pages

Choose your research edition.

Industry ResearchInactivated Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Inactivated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Inactivated Vaccine include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Inactivated Vaccine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inactivated Vaccine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inactivated Vaccine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Inactivated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Inactivated Vaccine Segment by Company

Johnson & Johnson(U.S.)

Merck & Co(U.S.)

Pfizer(U.S.)

GlaxoSmithKline(U.K.)

Serum Institute of India Pvt(India)

Sanofi Pasteur(France)

MedImmune(U.S.)

Emergent BioSolutions(U.S.)

CSL Limited(Australia)

Astellas Pharma(Japan)

Inactivated Vaccine Segment by Type

Children Inactivated Vaccine

Adult Inactivated Vaccine

Inactivated Vaccine Segment by Application

Hospital

Medical Center

Inactivated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Inactivated Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Vaccine industry.

Chapter 3: Detailed analysis of Inactivated Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Vaccinerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Children Inactivated Vaccine Table 3. Key Players of Adult Inactivated Vaccine Table 4. Global Inactivated Vaccine Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Medical Center Table 7. Global Inactivated Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Inactivated Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Inactivated Vaccine Market Share by Region (2021-2026) Table 10. Global Inactivated Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Inactivated Vaccine Market Share by Region (2027-2032) Table 12. Inactivated Vaccine Industry Trends Table 13. Inactivated Vaccine Industry Drivers Table 14. Inactivated Vaccine Industry Opportunities and Challenges Table 15. Inactivated Vaccine Industry Restraints Table 16. Global Inactivated Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Inactivated Vaccine Revenue Market Share by Company (2021-2026) Table 18. Global Inactivated Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Inactivated Vaccine Key Company Head Office and Area Served Table 20. Global Inactivated Vaccine Company, Product Type & Application Table 21. Global Inactivated Vaccine Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Inactivated Vaccine Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Inactivated Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Inactivated Vaccine Revenue Market Share by Type (2027-2032) Table 29. Global Inactivated Vaccine Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Inactivated Vaccine Revenue Market Share by Application (2021-2026) Table 33. Global Inactivated Vaccine Revenue Market Share by Application (2027-2032) Table 34. Johnson & Johnson(U.S.) Company Information Table 35. Johnson & Johnson(U.S.) Business Overview Table 36. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio Table 38. Johnson & Johnson(U.S.) Recent Development Table 39. Merck & Co(U.S.) Company Information Table 40. Merck & Co(U.S.) Business Overview Table 41. Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Merck & Co(U.S.) Inactivated Vaccine Product Portfolio Table 43. Merck & Co(U.S.) Recent Development Table 44. Pfizer(U.S.) Company Information Table 45. Pfizer(U.S.) Business Overview Table 46. Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Pfizer(U.S.) Inactivated Vaccine Product Portfolio Table 48. Pfizer(U.S.) Recent Development Table 49. GlaxoSmithKline(U.K.) Company Information Table 50. GlaxoSmithKline(U.K.) Business Overview Table 51. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio Table 53. GlaxoSmithKline(U.K.) Recent Development Table 54. Serum Institute of India Pvt(India) Company Information Table 55. Serum Institute of India Pvt(India) Business Overview Table 56. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio Table 58. Serum Institute of India Pvt(India) Recent Development Table 59. Sanofi Pasteur(France) Company Information Table 60. Sanofi Pasteur(France) Business Overview Table 61. Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio Table 63. Sanofi Pasteur(France) Recent Development Table 64. MedImmune(U.S.) Company Information Table 65. MedImmune(U.S.) Business Overview Table 66. MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. MedImmune(U.S.) Inactivated Vaccine Product Portfolio Table 68. MedImmune(U.S.) Recent Development Table 69. Emergent BioSolutions(U.S.) Company Information Table 70. Emergent BioSolutions(U.S.) Business Overview Table 71. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio Table 73. Emergent BioSolutions(U.S.) Recent Development Table 74. CSL Limited(Australia) Company Information Table 75. CSL Limited(Australia) Business Overview Table 76. CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. CSL Limited(Australia) Inactivated Vaccine Product Portfolio Table 78. CSL Limited(Australia) Recent Development Table 79. Astellas Pharma(Japan) Company Information Table 80. Astellas Pharma(Japan) Business Overview Table 81. Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio Table 83. Astellas Pharma(Japan) Recent Development Table 84. North America Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 85. North America Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 86. North America Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 87. North America Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 88. North America Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Inactivated Vaccine Market Size by Country (2021-2026) Table 90. North America Inactivated Vaccine Market Size by Country (2027-2032) Table 91. Europe Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 92. Europe Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 93. Europe Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 94. Europe Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 95. Europe Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Inactivated Vaccine Market Size by Country (2021-2026) Table 97. Europe Inactivated Vaccine Market Size by Country (2027-2032) Table 98. China Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 99. China Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 100. China Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 101. China Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 102. Asia Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 103. Asia Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 104. Asia Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 105. Asia Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 106. Asia Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Inactivated Vaccine Market Size by Country (2021-2026) Table 108. Asia Inactivated Vaccine Market Size by Country (2027-2032) Table 109. South America, Middle East & Africa Inactivated Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 110. South America, Middle East & Africa Inactivated Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 111. South America, Middle East & Africa Inactivated Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 112. South America, Middle East & Africa Inactivated Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 113. South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2021-2026) Table 115. South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Inactivated Vaccine Product Image Figure 2. Global Inactivated Vaccine Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Inactivated Vaccine Market Share by Type: 2025 VS 2032 Figure 4. Children Inactivated Vaccine Image Figure 5. Adult Inactivated Vaccine Image Figure 6. Global Inactivated Vaccine Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Inactivated Vaccine Market Share by Application: 2025 VS 2032 Figure 8. Hospital Image Figure 9. Medical Center Image Figure 10. Global Inactivated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 12. Global Inactivated Vaccine Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global Inactivated Vaccine Market Share by Players in 2025 Figure 15. Global Top 5 and 10 Inactivated Vaccine Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Inactivated Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Inactivated Vaccine Revenue Market Share by Type (2021-2032) Figure 19. Global Inactivated Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Inactivated Vaccine Revenue Market Share by Application (2021-2032) Figure 21. North America Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 22. North America Inactivated Vaccine Market Share by Type (2021-2032) Figure 23. North America Inactivated Vaccine Market Share by Application (2021-2032) Figure 24. North America Inactivated Vaccine Market Share by Country (2021-2032) Figure 25. United States Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 26. Canada Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 27. Mexico Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 28. Europe Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 29. Europe Inactivated Vaccine Market Share by Type (2021-2032) Figure 30. Europe Inactivated Vaccine Market Share by Application (2021-2032) Figure 31. Europe Inactivated Vaccine Market Share by Country (2021-2032) Figure 32. Germany Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 33. France Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 34. U.K. Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 35. Italy Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 36. Russia Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 38. China Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 39. China Inactivated Vaccine Market Share by Type (2021-2032) Figure 40. China Inactivated Vaccine Market Share by Application (2021-2032) Figure 41. Asia Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 42. Asia Inactivated Vaccine Market Share by Type (2021-2032) Figure 43. Asia Inactivated Vaccine Market Share by Application (2021-2032) Figure 44. Asia Inactivated Vaccine Market Share by Country (2021-2032) Figure 45. Japan Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 46. South Korea Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 49. India Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 50. Australia Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Inactivated Vaccine Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa Inactivated Vaccine Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa Inactivated Vaccine Market Share by Country (2021-2032) Figure 55. Brazil Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 56. South Africa Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 58. Turkey Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 59. Argentina Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 60. UAE Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 61. Egypt Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 62. Chile Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • Children Inactivated Vaccine
  • Adult Inactivated Vaccine
Applications
  • Hospital
  • Medical Center
Companies covered
  • Johnson & Johnson(U.S.)
  • Merck & Co(U.S.)
  • Pfizer(U.S.)
  • GlaxoSmithKline(U.K.)
  • Serum Institute of India Pvt(India)
  • Sanofi Pasteur(France)
  • MedImmune(U.S.)
  • Emergent BioSolutions(U.S.)
  • CSL Limited(Australia)
  • Astellas Pharma(Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Inactivated Vaccine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Children Inactivated Vaccine
  5. 1.2.3 Adult Inactivated Vaccine
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Inactivated Vaccine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Medical Center
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global Inactivated Vaccine Growth Trends by Region
  12. 1.5.1 Global Inactivated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 Inactivated Vaccine Market Size by Region (2021-2026)
  14. 1.5.3 Inactivated Vaccine Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global Inactivated Vaccine Market Dynamics
  1. 2.1 Inactivated Vaccine Industry Trends
  2. 2.2 Inactivated Vaccine Industry Drivers
  3. 2.3 Inactivated Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Vaccine Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Inactivated Vaccine Revenue by Company (2021-2026)
  2. 3.2 Global Inactivated Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Inactivated Vaccine Key Company Head office and Area Served
  4. 3.4 Global Inactivated Vaccine Company, Product Type & Application
  5. 3.5 Global Inactivated Vaccine Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Inactivated Vaccine Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Inactivated Vaccine Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Inactivated Vaccine Tier 1, Tier 2, and Tier 3
4 Inactivated Vaccine Market by Type
  1. 4.1 Global Inactivated Vaccine Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Inactivated Vaccine Market Size by Type (2021-2032)
  3. 4.3 Global Inactivated Vaccine Market Size Share by Type (2021-2032)
5 Inactivated Vaccine Market by Application
  1. 5.1 Global Inactivated Vaccine Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Inactivated Vaccine Market Size by Application (2021-2032)
  3. 5.3 Global Inactivated Vaccine Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Johnson & Johnson(U.S.)
  2. 6.1.1 Johnson & Johnson(U.S.) Company Information
  3. 6.1.2 Johnson & Johnson(U.S.) Business Overview
  4. 6.1.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
  6. 6.1.5 Johnson & Johnson(U.S.) Recent Developments
  7. 6.2 Merck & Co(U.S.)
  8. 6.2.1 Merck & Co(U.S.) Company Information
  9. 6.2.2 Merck & Co(U.S.) Business Overview
  10. 6.2.3 Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
  12. 6.2.5 Merck & Co(U.S.) Recent Developments
  13. 6.3 Pfizer(U.S.)
  14. 6.3.1 Pfizer(U.S.) Company Information
  15. 6.3.2 Pfizer(U.S.) Business Overview
  16. 6.3.3 Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
  18. 6.3.5 Pfizer(U.S.) Recent Developments
  19. 6.4 GlaxoSmithKline(U.K.)
  20. 6.4.1 GlaxoSmithKline(U.K.) Company Information
  21. 6.4.2 GlaxoSmithKline(U.K.) Business Overview
  22. 6.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
  24. 6.4.5 GlaxoSmithKline(U.K.) Recent Developments
  25. 6.5 Serum Institute of India Pvt(India)
  26. 6.5.1 Serum Institute of India Pvt(India) Company Information
  27. 6.5.2 Serum Institute of India Pvt(India) Business Overview
  28. 6.5.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
  30. 6.5.5 Serum Institute of India Pvt(India) Recent Developments
  31. 6.6 Sanofi Pasteur(France)
  32. 6.6.1 Sanofi Pasteur(France) Company Information
  33. 6.6.2 Sanofi Pasteur(France) Business Overview
  34. 6.6.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
  36. 6.6.5 Sanofi Pasteur(France) Recent Developments
  37. 6.7 MedImmune(U.S.)
  38. 6.7.1 MedImmune(U.S.) Company Information
  39. 6.7.2 MedImmune(U.S.) Business Overview
  40. 6.7.3 MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
  42. 6.7.5 MedImmune(U.S.) Recent Developments
  43. 6.8 Emergent BioSolutions(U.S.)
  44. 6.8.1 Emergent BioSolutions(U.S.) Company Information
  45. 6.8.2 Emergent BioSolutions(U.S.) Business Overview
  46. 6.8.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
  48. 6.8.5 Emergent BioSolutions(U.S.) Recent Developments
  49. 6.9 CSL Limited(Australia)
  50. 6.9.1 CSL Limited(Australia) Company Information
  51. 6.9.2 CSL Limited(Australia) Business Overview
  52. 6.9.3 CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
  54. 6.9.5 CSL Limited(Australia) Recent Developments
  55. 6.10 Astellas Pharma(Japan)
  56. 6.10.1 Astellas Pharma(Japan) Company Information
  57. 6.10.2 Astellas Pharma(Japan) Business Overview
  58. 6.10.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
  60. 6.10.5 Astellas Pharma(Japan) Recent Developments
7 North America
  1. 7.1 North America Inactivated Vaccine Market Size (2021-2032)
  2. 7.2 North America Inactivated Vaccine Market Size by Type
  3. 7.2.1 North America Inactivated Vaccine Market Size by Type (2021-2026)
  4. 7.2.2 North America Inactivated Vaccine Market Size by Type (2027-2032)
  5. 7.2.3 North America Inactivated Vaccine Market Share by Type (2021-2032)
  6. 7.3 North America Inactivated Vaccine Market Size by Application
  7. 7.3.1 North America Inactivated Vaccine Market Size by Application (2021-2026)
  8. 7.3.2 North America Inactivated Vaccine Market Size by Application (2027-2032)
  9. 7.3.3 North America Inactivated Vaccine Market Share by Application (2021-2032)
  10. 7.4 North America Inactivated Vaccine Market Size by Country
  11. 7.4.1 North America Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Inactivated Vaccine Market Size by Country (2021-2026)
  13. 7.4.3 North America Inactivated Vaccine Market Size by Country (2027-2032)
  14. 7.4.4 North America Inactivated Vaccine Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Inactivated Vaccine Market Size (2021-2032)
  2. 8.2 Europe Inactivated Vaccine Market Size by Type
  3. 8.2.1 Europe Inactivated Vaccine Market Size by Type (2021-2026)
  4. 8.2.2 Europe Inactivated Vaccine Market Size by Type (2027-2032)
  5. 8.2.3 Europe Inactivated Vaccine Market Share by Type (2021-2032)
  6. 8.3 Europe Inactivated Vaccine Market Size by Application
  7. 8.3.1 Europe Inactivated Vaccine Market Size by Application (2021-2026)
  8. 8.3.2 Europe Inactivated Vaccine Market Size by Application (2027-2032)
  9. 8.3.3 Europe Inactivated Vaccine Market Share by Application (2021-2032)
  10. 8.4 Europe Inactivated Vaccine Market Size by Country
  11. 8.4.1 Europe Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Inactivated Vaccine Market Size by Country (2021-2026)
  13. 8.4.3 Europe Inactivated Vaccine Market Size by Country (2027-2032)
  14. 8.4.4 Europe Inactivated Vaccine Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Inactivated Vaccine Market Size (2021-2032)
  2. 9.2 China Inactivated Vaccine Market Size by Type
  3. 9.2.1 China Inactivated Vaccine Market Size by Type (2021-2026)
  4. 9.2.2 China Inactivated Vaccine Market Size by Type (2027-2032)
  5. 9.2.3 China Inactivated Vaccine Market Share by Type (2021-2032)
  6. 9.3 China Inactivated Vaccine Market Size by Application
  7. 9.3.1 China Inactivated Vaccine Market Size by Application (2021-2026)
  8. 9.3.2 China Inactivated Vaccine Market Size by Application (2027-2032)
  9. 9.3.3 China Inactivated Vaccine Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Inactivated Vaccine Market Size (2021-2032)
  2. 10.2 Asia Inactivated Vaccine Market Size by Type
  3. 10.2.1 Asia Inactivated Vaccine Market Size by Type (2021-2026)
  4. 10.2.2 Asia Inactivated Vaccine Market Size by Type (2027-2032)
  5. 10.2.3 Asia Inactivated Vaccine Market Share by Type (2021-2032)
  6. 10.3 Asia Inactivated Vaccine Market Size by Application
  7. 10.3.1 Asia Inactivated Vaccine Market Size by Application (2021-2026)
  8. 10.3.2 Asia Inactivated Vaccine Market Size by Application (2027-2032)
  9. 10.3.3 Asia Inactivated Vaccine Market Share by Application (2021-2032)
  10. 10.4 Asia Inactivated Vaccine Market Size by Country
  11. 10.4.1 Asia Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Inactivated Vaccine Market Size by Country (2021-2026)
  13. 10.4.3 Asia Inactivated Vaccine Market Size by Country (2027-2032)
  14. 10.4.4 Asia Inactivated Vaccine Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Inactivated Vaccine Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Inactivated Vaccine Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Inactivated Vaccine Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Inactivated Vaccine Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Inactivated Vaccine Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Inactivated Vaccine Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Inactivated Vaccine Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Inactivated Vaccine Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Inactivated Vaccine Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Inactivated Vaccine Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Inactivated Vaccine Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Inactivated Vaccine Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst